Monoclonal Antibodies in Veterinary Health Market Size to Grow at 17.13% CAGR by 2034

The monoclonal antibodies in veterinary health market size reached US$ 1.45 billion in 2025 and is anticipate to increase to US$ 1.69 billion in 2026. By 2034, the market is forecasted to achieve a value of around US$ 6.00 billion, growing at a CAGR of 17.13%.

Ottawa, Nov. 10, 2025 (GLOBE NEWSWIRE) -- The monoclonal antibodies in veterinary health market size was valued at USD 1.23 billion in 2024 and is predicted to hit around USD 6.00 billion by 2034, rising at a 17.13% CAGR, a study published by Towards Healthcare a sister firm of Precedence Research.

The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.towardshealthcare.com/download-sample/5507

Key Takeaways

North America was dominant in the market by 44% share in 2024.
Asia Pacific is expected to grow at the fastest CAGR in the coming years.
By animal type, the dog segment held a major revenue share of the market in 2024.
By application, the dermatology segment led the market in 2024.
By application, the pain segment is expected to grow notably during 2025-2034.
By end-user, the veterinary hospital segment accounted for the largest share of the market in 2024.

Exposure to Novelty & Raising Availability: How is the Market Impacting?

Primarily, the global monoclonal antibodies in veterinary health market covers highly specific proteins that are utilised in the treatment of diseases in animals. The market is prominently fueled by ongoing technological breakthroughs in antibody production and a rising focus on selective, non-antibiotic therapies for livestock. Whereas, the latest developments are comprising the establishment of species-specific mAbs, especially the canine parvovirus antibody with conditional approval, and expanded commercial availability of products for osteoarthritis in dogs and cats, like Librela and Solensia, respectively.

What are the major Drivers in the Market?

A crucial factor involved in the overall monoclonal antibodies in veterinary health market is a rise in innovations in antibody production, particularly recombinant DNA technology and hybridoma methods. However, numerous collaborations among pharmaceutical, biotech, and research institutions boost the progression of novel monoclonal antibody therapies for animal diseases. Nowadays, the widespread pet owners are accelerating expenditure on their pets' healthcare, which fuels demand for advanced and efficacious treatments.

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

What are the Significant Drifts in the Market?

In February 2025, Nona Biosciences, a global biotechnology entered into a strategic alliance with Invetx, Inc., to establish next-generation animal health biotherapeutics using Nona's HCAb Harbour Mice platform.
In February 2024, Rejuvenate Bio partnered with a major animal health company to evolve gene therapy for canine osteoarthritis.

What is the Developing Limitation in the Market?

The market is mainly facing issues due to the complex regulatory process, under the various agencies, including the FDA's Center for Veterinary Medicine (CVM) and the USDA's Center for Veterinary Biologics (CVB) probably regulating several products.

Regional Analysis

What Made North America Dominant in the Market in 2024?

In the monoclonal antibodies in veterinary health market, North America captured the biggest share by 44% in 2024. The wider contribution of rising pet ownership, with expanded gene editing and new therapeutic developments, is allowing more accurate and efficient monoclonal antibodies for veterinary use. The US market is emphasising R&D efforts in oncology and infectious diseases in livestock.

In April 2025, the U.S. Food and Drug Administration (FDA) announced an innovative strategy to phase out the need for animal testing in the development of mAbs and other drugs.

How did the Asia Pacific Expand Notably in the Market in 2024?

In the prospective period, the Asia Pacific is anticipated to be the fastest-growing region in the monoclonal antibodies in veterinary health market. This will be mainly propelled by the increasing awareness regarding animal health and welfare, technological breakthroughs in biotech, and government initiatives are support animal health. The Fleming Fund Regional Grant, Antimicrobial Resistance and One Health in South East Asia (AMROH SEA), powered by the Asia-Pacific Centre for Animal Health at the University of Melbourne, is offering assistance to tackle AMR in animal health (terrestrial and aquatic).

Become a valued research partner with us - https://www.towardshealthcare.com/schedule-meeting

Segmental Insights

By Animal Type Analysis

Why did the Dog Segment Lead the Market in 2024?

The dog segment registered dominance with a major share of the monoclonal antibodies in veterinary health market in 2024. According to many surveys, it was found that dog is a family member of the numerous homes, which is impacting the pet ownership rates. Additionally, conditional USDA approval for Elanco's Canine Parvovirus Monoclonal Antibody (CPMA) in puppies, Zoetis's Health Canada approval of Lenivia (izenivetmab) for osteoarthritis pain, and Elanco's investment are accelerating the production of CPMA.

By Application Analysis

Why the Dermatology Segment Dominated the Market in 2024?

The dermatology segment held the largest revenue share of the market in 2024. The globe is facing a huge rise in atopic and allergic dermatitis, which is more common in pets, specifically in dogs. The market is encouraging the use of Zoetis's Cytopoint (lokivetmab) to manage atopic dermatitis in dogs, and Merck's Gilvetmab in a few kinds of cancers, like mast cell tumours and melanomas.

Although the pain segment is estimated to expand at a lucrative CAGR in the coming era. The rising cases of osteoarthritis, cancer, and atopic dermatitis in companion animals, as well as the approval and post-market data of Librela for dogs and Solensia for cats, are influencing the comprehensive segmental progression. Nowadays, researchers are aiming at the development of monoclonal antibodies for targeting other pain-related pathways, including voltage-gated sodium channels, to interrupt pain signal transmission.

By End-user Analysis

How did the Veterinary Hospital Segment Dominate the Market in 2024?

The veterinary hospital segment captured a major share of the monoclonal antibodies in veterinary health market in 2024. Globally escalating focus on enhancing animal health, and the use of advanced recombinant DNA and hybridoma technology, with broader efficacy and specificity in producing monoclonal antibodies, is leveraging veterinary developments in hospitals. Also, hospitals widely foster indigenous products, physiotherapy, and highly sophisticated diagnostic solutions.

Browse More Insights of Towards Healthcare:

The monoclonal antibody market targeting asthma and COPD is witnessing robust growth, with revenues expected to surge to several hundred million dollars by the end of the forecast period from 2025 to 2034.

The monoclonal antibody discovery platform market is advancing rapidly on a global scale, with projected revenues reaching hundreds of millions during the same period.

The global monoclonal antibodies market was valued at USD 254.89 billion in 2024, increased to USD 286.6 billion in 2025, and is anticipated to reach approximately USD 823.31 billion by 2034, expanding at a CAGR of 12.44% from 2025 to 2034.

The global biologics safety testing market was valued at USD 4.03 billion in 2024, grew to USD 4.58 billion in 2025, and is projected to hit nearly USD 14.45 billion by 2034, reflecting a CAGR of 13.64% during the forecast period.

The global oncology biosimilars market stood at USD 6.7 billion in 2024, rose to USD 7.94 billion in 2025, and is expected to reach around USD 36.23 billion by 2034, growing at a remarkable CAGR of 18.47% between 2025 and 2034.

What are the Key Developments in the Market?

In October 2025, Akston introduced a clinical study at Purdue University for its Ambifect immuno-enhancing therapy, created to induce antibodies targeting PD-L1 in dogs with solid tumours.
In June 2025, Vetigenics unveiled CHECKMATE K9, a first dual immune heckpoint inhibitor study in dogs with solid tumours.

Monoclonal Antibodies in Veterinary Health Market Key Players List

Zoetis
Merck & Co, Inc.
Elanco
Boehringer Ingelheim GmbH
Indian Immunologicals Ltd
Virbac

Segments Covered in the Report

By Animal Type

Dogs
Others

By Application

Dermatology
Pain
Others

By End-user

Veterinary Hospitals
Others

By Region

North America
- U.S.
- Canada
Asia Pacific
- China
- Japan
- India
- South Korea
- Thailand
Europe
- Germany
- UK
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
Latin America
- Brazil
- Mexico
- Argentina
Middle East and Africa (MEA)
- South Africa
- UAE
- Saudi Arabia
- Kuwait

Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/checkout/5507

Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.

Access the Dashboard: https://www.towardshealthcare.com/access-dashboard

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

Europe Region: +44 778 256 0738

North America Region: +1 8044 4193 44

APAC Region: +91 9356 9282 04

Web: https://www.towardshealthcare.com

Our Trusted Data Partners

Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.